Supplementary Appendix Sensitivity analysis

Primary outcome

1. All-cause mortality

	Intensive	Standa	ard		Risk Ratio	Risk Ratio
Study or Subgroup	Events Tot	al Events	Total	Weight	M-H, Fixed, 99% C	M-H, Fixed, 99% CI
Dargie	8 1	0 5	114	2.2%	1.66 [0.40, 6.91]	-
HOME	9 19	6 6	194	2.7%	1.48 [0.39, 5.63]	
PROactive	177 260	5 186	2633	82.6%	0.96 [0.74, 1.25]	-
UGDP a	64 4	08 21	205	12.5%	1.53 [0.83, 2.82]	+-
Total (99% CI)	331	9	3146	100.0%	1.06 [0.84, 1.34]	•
Total events	258	218				
Heterogeneity: Chi ² = 4	4.42, df = 3 (P	= 0.22); I ² =	32%			0.2 0.5 1 2 5
Test for overall effect:	Z = 0.67 (P = 0.000)	.50)			Fa	0.2 0.5 1 2 5 avours experimental Favours control

2. Cardiovascular deaths

	Intens	ive	Standa	ard		Risk Ratio	Risk	Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 99% C	I M-H, Rand	dom, 99% CI
Dargie	5	110	4	114	18.5%	1.30 [0.24, 7.04]		-
HOME	4	196	1	194	9.0%	3.96 [0.22, 69.69]		-
PROactive	127	2605	136	2633	40.7%	0.94 [0.69, 1.29]		•
UGDP a	53	408	10	205	31.8%	2.66 [1.13, 6.29]		-
Total (99% CI)		3319		3146	100.0%	1.58 [0.60, 4.17]	•	•
Total events	189		151					
Heterogeneity: Tau ² =	0.33; Chi ²	= 10.0	9, df = 3 (P = 0.0	$(2); I^2 = 70$	%	+ + +	+ + + + + + + + + + + + + + + + + + + +
Test for overall effect:	Z = 1.22 (I	P = 0.2	2)			F	0.002 0.1 avours experimental	1 10 500 Favours control

Macro-vascular events

1. All myocardial infarctions

	Intens	ive	Standa	ard		Risk Ratio	Risk	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 99% C	I M-H, Fix	red, 99% CI	
HOME	8	196	5	194	14.6%	1.58 [0.37, 6.72]		—	•
UGDP a	57	408	22	205	85.4%	1.30 [0.71, 2.39]	_	_	
Total (99% CI)		604		399	100.0%	1.34 [0.77, 2.35]	•	•	
Total events	65		27						
Heterogeneity: Chi ² = 0	0.10, df = 1	1 (P = 0).75); I ² =	0%			0.05 0.2	1 5	 20
Test for overall effect: 2	Z = 1.36 (I	P = 0.17	7)			Fa	avours experimental		

2. Non-fatal myocardial infarctions

	Intens	ive	Standa	ard		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 99% CI	M-H, Fixed, 99% CI
HOME	4	196	4	194	2.3%	0.99 [0.16, 6.00]	
PROactive	119	2605	144	2633	82.4%	0.84 [0.61, 1.14]	
UGDP a	32	408	20	205	15.3%	0.80 [0.40, 1.62]	
Total (99% CI)		3209		3032	100.0%	0.83 [0.63, 1.10]	•
Total events	155		168				
Heterogeneity: Chi ² =	0.08, df = 3	2 (P = 0).96); I ² =	0%			0.2 0.5 1 2 5
Test for overall effect:	Z = 1.66 (I	P = 0.10	0)			Fa	avours experimental Favours control

3. All strokes

	Intens	ive	Standa	ard		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 99% C	M-H, Fixed, 99% CI
HOME	1	196	1	194	0.9%	0.99 [0.03, 37.46]	
PROactive	86	2605	107	2633	99.1%	0.81 [0.56, 1.17]	
UGDP a	0	408	0	205		Not estimable	
Total (99% CI)		3209		3032	100.0%	0.81 [0.57, 1.17]	•
Total events	87		108				
Heterogeneity: Chi2 = 0	0.02, df =	1 (P = 0	0.89); I ² =	0%			0.005 0.1 1 10 000
Test for overall effect:	Z = 1.45 (I	P = 0.1	5)			Fa	0.005 0.1 1 10 200 avours experimental Favours control

4. Congestive Heart Failure

	Intensive	Standard		Risk Ratio	Risk Ratio
Study or Subgroup	Events Tota	I Events Tota	Weight	M-H, Fixed, 99% CI	M-H, Fixed, 99% CI
Dargie	7 110	4 114	1.8%	1.81 [0.37, 8.78]	
HOME	3 196	6 4 194	1.8%	0.74 [0.11, 5.22]	
PROactive	281 2605	198 2633	88.7%	1.43 [1.14, 1.80]	
UGDP a	51 398	3 13 205	7.7%	2.02 [0.94, 4.36]	-
Total (99% CI)	3309	3146	100.0%	1.47 [1.19, 1.83]	•
Total events	342	219			
Heterogeneity: Chi ² = 2	2.15, df = 3 (P =	0.54); I ² = 0%		•	
Test for overall effect:	Z = 4.64 (P < 0.	00001)		Fav	0.1 0.2 0.5 1 2 5 10 vours experimental Favours control

Micro-vascular events

1. New or worsening retinopathy

	Intensi	ive	Standa	ard		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 99%	CI M-H, Fixed, 99% CI
HOME	1	196	0	194	0.6%	2.97 [0.04, 197.68	s ₁ +
UGDP a	98	291	67	156	99.4%	0.78 [0.57, 1.08	sj -
Total (99% CI)		487		350	100.0%	0.80 [0.58, 1.09	1
Total events	99		67				
Heterogeneity: Chi ² = 0	0.67, df =	1 (P = 0).41); I ² =	0%			0.2 0.5 1 2 5
Test for overall effect:	Z = 1.84 (I	= 0.0°	7)				Favours experimental Favours control

2. New or worsening microalbuminuria

	Intens	ive	Standa	ard		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 99% CI	M-H, Fixed, 99% CI
HOME	15	196	14	194	2.4%	1.06 [0.42, 2.66]	
PROactive	555	2218	563	2225	95.5%	0.99 [0.87, 1.13]	-
UGDP a	22	384	9	186	2.1%	1.18 [0.44, 3.20]	-
Total (99% CI)		2798		2605	100.0%	0.99 [0.87, 1.13]	•
Total events	592		586				
Heterogeneity: Chi2 =	0.25, df =	2 (P = 0	0.88); I ² =	0%		=	1 1 1 1 1
Test for overall effect:	Z = 0.11 (P = 0.93	2)			Fav	0.5 0.7 1 1.5 2 ours experimental Favours control

3. Fatal or non fatal amputation

	Intensiv	ve	Standa	ard		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 99% C	CI M-H, Fixed, 99% CI
HOME	2	196	1	194	3.4%	1.98 [0.09, 45.92]	<u></u> -
PROactive	26	2605	26	2633	87.5%	1.01 [0.50, 2.06]	-
UGDP a	1	392	2	194	9.1%	0.25 [0.01, 5.76]	•
Total (99% CI)		3193		3021	100.0%	0.97 [0.50, 1.90]	•
Total events	29		29				
Heterogeneity: Chi2 =	1.61, df = 2	P = 0).45); I ² =	0%			10005
Test for overall effect:	Z = 0.10 (P	0.92	2)			F	0.005 0.1 1 10 200 avours experimental Favours control

4. Peripheral Vascular Events

	Intens	ive	Standa	ard		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 99% (CI M-H, Fixed, 99% CI
HOME	7	196	8	194	8.5%	0.87 [0.23, 3.20]
PROactive	80	2605	65	2633	68.7%	1.24 [0.81, 1.90] —
UGDP a	59	367	16	182	22.7%	1.83 [0.92, 3.64	j
Total (99% CI)		3168		3009	100.0%	1.34 [0.95, 1.90]	ı •
Total events	146		89				
Heterogeneity: Chi ² = 2	2.30, df = 2	2 (P = 0).32); I ² =	13%			02 05 1 2 5
Test for overall effect:	Z = 2.20 (1	P = 0.03	3)			F	0.2 0.5 1 2 5 Favours experimental Favours control